

Masanori Isaka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9135958/publications.pdf>

Version: 2024-02-01

14
papers

300
citations

933447

10
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

332
citing authors

#	ARTICLE	IF	CITATIONS
1	A greater effect on clarithromycin resistance of <i>mef</i> (A)-associated <i>msr</i> (D) than <i>mef</i> (E)-associated <i>msr</i> (D) in <i>Streptococcus pyogenes</i> . <i>Microbiology and Immunology</i> , 2022, , .	1.4	0
2	<i>Streptococcus pyogenes</i> TrxSR Two-Component System Regulates Biofilm Production in Acidic Environments. <i>Infection and Immunity</i> , 2021, 89, e0036021.	2.2	3
3	Induction of antibody responses in mice immunized intranasally with Type I interferon as adjuvant and synergistic effect of chitosan. <i>Microbiology and Immunology</i> , 2020, 64, 610-619.	1.4	3
4	Functional Predominance of <i>msr</i> (D), Which Is More Effective as <i>mef</i> (A)-Associated Than <i>mef</i> (E)-Associated, Over <i>mef</i> (A)/ <i>mef</i> (E) in Macrolide Resistance in <i>Streptococcus pyogenes</i> . <i>Microbial Drug Resistance</i> , 2018, 24, 1089-1097.	2.0	20
5	The YvqE two-component system controls biofilm formation and acid production in <i>Streptococcus pyogenes</i> . <i>Apmis</i> , 2016, 124, 574-585.	2.0	12
6	Predominant role of <i>msr</i> (D) over <i>mef</i> (A) in macrolide resistance in <i>Streptococcus pyogenes</i> . <i>Microbiology (United Kingdom)</i> , 2016, 162, 46-52.	1.8	36
7	A Palindromic CpG-Containing Phosphodiester Oligodeoxynucleotide as a Mucosal Adjuvant Stimulates Plasmacytoid Dendritic Cell-Mediated TH1 Immunity. <i>PLoS ONE</i> , 2014, 9, e88846.	2.5	17
8	Analysis of two-component sensor proteins involved in the response to acid stimuli in <i>Streptococcus pyogenes</i> . <i>Microbiology (United Kingdom)</i> , 2011, 157, 3187-3194.	1.8	24
9	Detection of invasive protein profile of <i>Streptococcus pyogenes</i> M1 isolates from pharyngitis patients. <i>Apmis</i> , 2010, 118, 167-178.	2.0	24
10	Effects of Recombinant Cholera Toxin B Subunit (rCTB) on Cellular Immune Responses: Enhancement of Delayed-Type Hypersensitivity Following Intranasal Co-Administration of <i>Mycobacterium bovis</i> BCG with rCTB. <i>Microbiology and Immunology</i> , 2004, 48, 457-463.	1.4	9
11	Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine. <i>Vaccine</i> , 2004, 22, 3061-3068.	3.8	23
12	Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant. <i>Vaccine</i> , 2001, 19, 1460-1466.	3.8	74
13	Cytokine Responses to Recombinant Cholera Toxin B Subunit Produced by <i>Bacillus brevis</i> as a Mucosal Adjuvant. <i>Microbiology and Immunology</i> , 2001, 45, 111-117.	1.4	16
14	Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant. <i>Vaccine</i> , 1999, 18, 743-751.	3.8	39